Court rules for Emord in health claims case
This article was originally published in The Tan Sheet
Executive Summary
A federal court rules FDA must adhere to the First Amendment standard established in Pearson v. Shalala and allow certain qualified anti-carcinogenic claims for selenium, as sought by attorney Jonathan Emord. Clifton, Va.-based Emord & Associates sued FDA in 2009 on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship and supplement businesspersons Durk Pearson and Sandy Shaw, alleging FDA's approval of narrowly qualified health claims denied consumers accurate information (1"The Tan Sheet" Aug. 3, 2009, In Brief). In a May 27 2decision, the U.S. District Court for the District of Columbia calls FDA's position on QHCs "troubling" and says the agency "is obligated to at least consider the possibility of approving plaintiffs' proposed language with the addition of 'short, succinct, and accurate disclaimers.'
You may also be interested in...
Suit claims FDA "censorship" on QHCs
FDA's rejection of certain qualified health claims linking selenium to cancer prevention violates a federal court ruling that mandates a First Amendment standard for reviewing QHCs, Jonathan Emord asserts. The Clifton, Va.-based attorney filed a 1complaint July 30 in the U.S. District Court for the District of Columbia on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship, which Emord founded, and supplement businesspersons Durk Pearson and Sandy Shaw. FDA recently approved a number of narrowly qualified, essentially unusable QHCs for selenium in response to an Emord citizen petition (2"The Tan Sheet" June 29, 2009). "FDA has denied consumers accurate representations of nutrition science," the complaint states
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.